452 related articles for article (PubMed ID: 37813236)
1. Delivery of gene editing therapeutics.
Kevadiya BD; Islam F; Deol P; Zaman LA; Mosselhy DA; Ashaduzzaman M; Bajwa N; Routhu NK; Singh PA; Dawre S; Vora LK; Nahid S; Mathur D; Nayan MU; Baldi A; Kothari R; Patel TA; Madan J; Gounani Z; Bariwal J; Hettie KS; Gendelman HE
Nanomedicine; 2023 Nov; 54():102711. PubMed ID: 37813236
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
5. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
Li L; Hu S; Chen X
Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
[TBL] [Abstract][Full Text] [Related]
6. Clustered Regularly Interspaced Short Palindromic Repeats and Clustered Regularly Interspaced Short Palindromic Repeats-Associated Protein 9 System: Factors Affecting Precision Gene Editing Efficiency and Optimization Strategies.
Li J; Tang C; Liang G; Tian H; Lai G; Wu Y; Liu S; Zhang W; Liu S; Shao H
Hum Gene Ther; 2023 Dec; 34(23-24):1190-1203. PubMed ID: 37642232
[TBL] [Abstract][Full Text] [Related]
7. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
11. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 therapeutics: progress and prospects.
Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
[TBL] [Abstract][Full Text] [Related]
14. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
15. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.
Sharma G; Sharma AR; Bhattacharya M; Lee SS; Chakraborty C
Mol Ther; 2021 Feb; 29(2):571-586. PubMed ID: 33238136
[TBL] [Abstract][Full Text] [Related]
17. Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
Song N; Chu Y; Tang J; Yang D
Chembiochem; 2023 Aug; 24(16):e202300180. PubMed ID: 37183575
[TBL] [Abstract][Full Text] [Related]
18. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
19. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
